General Information of the Protein
Protein ID
PT01170
Protein Name
DNA topoisomerase 1
Secondarily
Protein Name
DNA topoisomerase I
Gene Name
TOP1
Sequence
MSGDHLHNDSQIEADFRLNDSHKHKDKHKDREHRHKEHKKEKDREKSKHSNSEHKDSEKKHKEKEKTKHKDGSSEKHKDKHKDRDKEKRKEEKVRASGDAKIKKEKENGFSSPPQIKDEPEDDGYFVPPKEDIKPLKRPRDEDDADYKPKKIKTEDTKKEKKRKLEEEEDGKLKKPKNKDKDKKVPEPDNKKKKPKKEEEQKWKWWEEERYPEGIKWKFLEHKGPVFAPPYEPLPENVKFYYDGKVMKLSPKAEEVATFFAKMLDHEYTTKEIFRKNFFKDWRKEMTNEEKNIITNLSKCDFTQMSQYFKAQTEARKQMSKEEKLKIKEENEKLLKEYGFCIMDNHKERIANFKIEPPGLFRGRGNHPKMGMLKRRIMPEDIIINCSKDAKVPSPPPGHKWKEVRHDNKVTWLVSWTENIQGSIKYIMLNPSSRIKGEKDWQKYETARRLKKCVDKIRNQYREDWKSKEMKVRQRAVALYFIDKLALRAGNEKEEGETADTVGCCSLRVEHINLHPELDGQEYVVEFDFLGKDSIRYYNKVPVEKRVFKNLQLFMENKQPEDDLFDRLNTGILNKHLQDLMEGLTAKVFRTYNASITLQQQLKELTAPDENIPAKILSYNRANRAVAILCNHQRAPPKTFEKSMMNLQTKIDAKKEQLADARRDLKSAKADAKVMKDAKTKKVVESKKKAVQRLEEQLMKLEVQATDREENKQIALGTSKLNYLDPRITVAWCKKWGVPIEKIYNKTQREKFAWAIDMADEDYEF
    Show/Hide
Organism
Homo sapiens, Human
Protein Classification
Enzyme
>
Isomerase
Function
Releases the supercoiling and torsional tension of DNA introduced during the DNA replication and transcription by transiently cleaving and rejoining one strand of the DNA duplex. Introduces a single-strand break via transesterification at a target site in duplex DNA. The scissile phosphodiester is attacked by the catalytic tyrosine of the enzyme, resulting in the formation of a DNA-(3'-phosphotyrosyl)-enzyme intermediate and the expulsion of a 5'-OH DNA strand. The free DNA strand then rotates around the intact phosphodiester bond on the opposing strand, thus removing DNA supercoils. Finally, in the religation step, the DNA 5'-OH attacks the covalent intermediate to expel the active-site tyrosine and restore the DNA phosphodiester backbone (By similarity). Regulates the alternative splicing of tissue factor (F3) pre-mRNA in endothelial cells. Involved in the circadian transcription of the core circadian clock component BMAL1 by altering the chromatin structure around the ROR response elements (ROREs) on the BMAL1 promoter.
    Show/Hide
Uniprot ID
Primary ID:
P11387

Secondarily ID:
A8KA78
E1P5W3
O43256
Q12855
Q12856
Q15610
Q5TFY3
Q9UJN0
    Show/Hide
Ensembl ID
ENSG00000198900
HGNC ID
HGNC:11986
Subcellular Location
Nucleus
Nucleolus
Nucleus
Nucleoplasm
Map of Molecular Bioactivity Related to the Protein
Map of Molecular Bioactivity Related to the Protein

Protein
Cell Line
Compound

Bioactivity Value:

<= 0.1 μM
> 0.1 μM and <= 10 μM
> 10 μM
Imprecise Activity
Table of Molecular Bioactivities Related to the Protein
Cell Line ID: CL000018 , HL-60
Compound ID Compound Name Compound Formula
CP0219181
7-ethyl-7-hydroxy-(7S)-7,8,11,13-tetrahydro-10H-[1,3]dioxolo[4,5-g]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-8,11-dione
   Show/Hide
C21H16N2O6
 1
1
IC50 = 27 nM
   TI
   LI
   LO
   TS
CP0236960
(19S)-19-ethyl-19-hydroxy-8-methyl-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione
   Show/Hide
C21H18N2O4
 1
1
IC50 = 38 nM
   TI
   LI
   LO
   TS
CP0048997
(20R)-7-ethyl-7-hydroxy-7,8,11,13-tetrahydro-10H-[1,3]dioxolo[5,4-g]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-8,11-dione
   Show/Hide
C21H16N2O6
 2
1
IC50 = 38 nM
   TI
   LI
   LO
   TS
2
IC50 = 67 nM
   TI
   LI
   LO
   TS
CP0383456
(5S)-16-amino-5-ethyl-5-hydroxy-7,18,20-trioxa-11,24-diazahexacyclo[11.11.0.02,11.04,9.015,23.017,21]tetracosa-1(24),2,4(9),13,15,17(21),22-heptaene-6,10-dione
   Show/Hide
C21H17N3O6
 1
1
IC50 = 48 nM
   TI
   LI
   LO
   TS
CP0184752
(20S)-15-chloro-7-ethyl-7-hydroxy-7,8,11,13-tetrahydro-10H-[1,3]dioxolo[5,4-g]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-8,11-dione
   Show/Hide
C21H15ClN2O6
 1
1
IC50 = 61 nM
   TI
   LI
   LO
   TS
CP0402355
(20R)-15-amino-7-ethyl-7-hydroxy-7,8,11,13-tetrahydro-10H-[1,3]dioxolo[5,4-g]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-8,11-dione
   Show/Hide
C21H17N3O6
 2
1
IC50 = 69 nM
   TI
   LI
   LO
   TS
2
IC50 = 76 nM
   TI
   LI
   LO
   TS
CP0535475
(19S)-8-chloro-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione
   Show/Hide
C20H15ClN2O4
 1
1
IC50 = 86 nM
   TI
   LI
   LO
   TS
CP0103674
(S)-10-Amino-4-ethyl-4-hydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione
   Show/Hide
C20H17N3O4
 1
1
IC50 = 110 nM
   TI
   LI
   LO
   TS
CP0193848
(20S)-4-Ethyl-4,9-dihydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione
   Show/Hide
C20H16N2O5
 1
1
IC50 = 110 nM
   TI
   LI
   LO
   TS
CP0562248
(20S)-9,10-Dichloro-4-ethyl-4-hydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione
   Show/Hide
C20H14Cl2N2O4
 1
1
IC50 = 110 nM
   TI
   LI
   LO
   TS
CP0516655
(20S)-9-Bromo-4-ethyl-4-hydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione
   Show/Hide
C20H15BrN2O4
 1
1
IC50 = 130 nM
   TI
   LI
   LO
   TS
CP0535949
(19S)-7-chloro-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaene-14,18-dione
   Show/Hide
C20H15ClN2O4
 1
1
IC50 = 140 nM
   TI
   LI
   LO
   TS
CP0538333
(19S)-7-amino-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaene-14,18-dione
   Show/Hide
C20H17N3O4
 1
1
IC50 = 140 nM
   TI
   LI
   LO
   TS
CP0522592
(5S)-5-ethyl-5-hydroxy-16-nitro-7,18,20-trioxa-11,24-diazahexacyclo[11.11.0.02,11.04,9.015,23.017,21]tetracosa-1(24),2,4(9),13,15,17(21),22-heptaene-6,10-dione
   Show/Hide
C21H15N3O8
 1
1
IC50 = 150 nM
   TI
   LI
   LO
   TS
CP0506653
(20S)-4-Ethyl-10-fluoro-4-hydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione
   Show/Hide
C20H15FN2O4
 1
1
IC50 = 160 nM
   TI
   LI
   LO
   TS
CP0538023
(20RS)-10-Chloro-4-ethyl-4-hydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione
   Show/Hide
C20H15ClN2O4
 1
1
IC50 = 190 nM
   TI
   LI
   LO
   TS
CP0375184
(20RS)-7-ethyl-7-hydroxy-15-nitro-7,8,11,13-tetrahydro-10H-[1,3]dioxolo[5,4-g]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-8,11-dione
   Show/Hide
C21H15N3O8
 1
1
IC50 = 220 nM
   TI
   LI
   LO
   TS
CP0862657
(20RS)-1N-(7-ethyl-7-hydroxy-8,11-dioxo-7,8,11,13-tetrahydro-10H-[1,3]dioxolo[5,4-g]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-15-yl)-2-aminoacetamide hydrochloride
   Show/Hide
C23H21ClN4O7
 2
1
IC50 = 260 nM
   TI
   LI
   LO
   TS
2
IC50 > 30000 nM
   TI
   LI
   LO
   TS
CP0402392
(19S)-19-ethyl-19-hydroxy-7-methyl-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaene-14,18-dione
   Show/Hide
C21H18N2O4
 1
1
IC50 = 300 nM
   TI
   LI
   LO
   TS
CP0498031
(20S)-4-Ethyl-9-fluoro-4-hydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione
   Show/Hide
C20H15FN2O4
 1
1
IC50 = 370 nM
   TI
   LI
   LO
   TS
CP0911716
(20RS)-7-ethyl-8,11-dioxo-7,8,11,13-tetrahydro-10H-[1,3]dioxolo[5,4-g]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-7-yl 2-aminoacetate hydrochloride
   Show/Hide
C23H20ClN3O7
 2
1
IC50 = 430 nM
   TI
   LI
   LO
   TS
2
IC50 = 2500 nM
   TI
   LI
   LO
   TS
CP0427012
(20RS)-10-Amino-4-ethyl-4-hydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione
   Show/Hide
C20H17N3O4
 2
1
IC50 = 440 nM
   TI
   LI
   LO
   TS
2
IC50 = 840 nM
   TI
   LI
   LO
   TS
CP0430301
(20RS)-8-ethyl-8-hydroxy-2,3,8,9,12,14-hexahydro-11H-[1,4]dioxino[3,2-g]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-9,12-dione
   Show/Hide
C22H18N2O6
 1
1
IC50 = 470 nM
   TI
   LI
   LO
   TS
CP0946416
(20RS)-sodium 2-hydroxy-2-(8-hydroxymethyl-9-oxo-9,11-dihydro[1,3]dioxolo[5,4-g]indolizino[1,2-b]quinolin-7-yl)butanoate
   Show/Hide
C21H17N2NaO7
 1
1
IC50 = 550 nM
   TI
   LI
   LO
   TS
CP0895218
(20RS)-2-Amino-N-(4-ethyl-4-hydroxy-3,13-dioxo-3,4,12,13-tetrahydro-1H-2-oxa-6,12a-diaza-dibenzo[b,h]fluoren-10-yl)-acetamide hydrochloride
   Show/Hide
C22H21ClN4O5
 2
1
IC50 = 570 nM
   TI
   LI
   LO
   TS
2
IC50 > 30000 nM
   TI
   LI
   LO
   TS
CP0464796
(19S)-19-ethyl-19-hydroxy-7-nitro-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaene-14,18-dione
   Show/Hide
C20H15N3O6
 1
1
IC50 = 640 nM
   TI
   LI
   LO
   TS
CP0036977
(S)-4-ethyl-4-hydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]florene-3,13-dione
   Show/Hide
C20H16N2O4
 1
1
IC50 = 680 nM
   TI
   LI
   LO
   TS
CP0912322
(20S)-sodium 2-hydroxy-2-(8-hydroxymethyl-9-oxo-9,11-dihydro[1,3]dioxolo[5,4-g]indolizino[1,2-b]quinolin-7-yl)butanoate
   Show/Hide
C21H17N2NaO7
 1
1
IC50 = 840 nM
   TI
   LI
   LO
   TS
CP0067633
(19S)-19-ethyl-8,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione
   Show/Hide
C20H16N2O5
 1
1
IC50 = 870 nM
   TI
   LI
   LO
   TS
CP0405259
(20RS)-4-Ethyl-4,10-dihydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione
   Show/Hide
C20H16N2O5
 1
1
IC50 = 900 nM
   TI
   LI
   LO
   TS
CP0093295
(S)-10-Dimethylaminomethyl-4-ethyl-4,9-dihydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione; hydrochloride
   Show/Hide
C23H23N3O5
 1
1
IC50 = 1000 nM
   TI
   LI
   LO
   TS
CP0549578
(20S)-4-Ethyl-4-hydroxy-3,13-dioxo-3,4,12,13-tetrahydro-1H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-9-carboxylic acid
   Show/Hide
C21H16N2O6
 1
1
IC50 = 1000 nM
   TI
   LI
   LO
   TS
CP0911715
10-Aziridin-1-ylmethyl-4-ethyl-4,9-dihydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione hydrochloride
   Show/Hide
C23H22ClN3O5
 1
1
IC50 = 1100 nM
   TI
   LI
   LO
   TS
CP0391268
(20R)-4-Ethyl-4-hydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione
   Show/Hide
C20H16N2O4
 2
1
IC50 = 1400 nM
   TI
   LI
   LO
   TS
2
IC50 = 1600 nM
   TI
   LI
   LO
   TS
CP0502205
(20RS)-4-Ethyl-4-hydroxy-10-methoxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione
   Show/Hide
C21H18N2O5
 1
1
IC50 = 1600 nM
   TI
   LI
   LO
   TS
CP0289533
(19S)-19-ethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaene-7-carbonitrile
   Show/Hide
C21H15N3O4
 1
1
IC50 = 1900 nM
   TI
   LI
   LO
   TS
CP0878540
(20RS)-Sodium salt; 2-hydroxy-2-(8-hydroxymethyl-9-oxo-9,11-dihydro-indolizino[1,2-b]quinolin-7-yl)-butyrate
   Show/Hide
C20H17N2NaO5
 1
1
IC50 = 2000 nM
   TI
   LI
   LO
   TS
CP0562637
(20RS)-4-(2-Bromo-ethyl)-4-hydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione
   Show/Hide
C20H15BrN2O4
 1
1
IC50 = 3100 nM
   TI
   LI
   LO
   TS
CP0890944
(20S)-disodium 2-hydroxy-2-(3-hydroxymethyl-9-olato-4-oxo-4,6-dihydroindolizino[1,2-b]quinolin-2-yl)butanoate
   Show/Hide
C20H16N2Na2O6
 1
1
IC50 = 3200 nM
   TI
   LI
   LO
   TS
CP0467581
(20RS)-8-ethyl-8-hydroxy-8,9,12,14-tetrahydro-11H-[1,3]dioxolo[5,4-f]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-9,12-dione
   Show/Hide
C21H16N2O6
 1
1
IC50 = 3800 nM
   TI
   LI
   LO
   TS
CP0454007
(20RS)-4-Hydroxy-4-methyl-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione
   Show/Hide
C19H14N2O4
 1
1
IC50 = 4000 nM
   TI
   LI
   LO
   TS
CP0946537
(20S)-sodium 2-(13-amino-8-hydroxymethyl-9-oxo-9,11-dihydro[1,3]dioxolo[5,4-g]indolizino[1,2-b]quinolin-7-yl)-2-hydroxybutanoate
   Show/Hide
C21H18N3NaO7
 1
1
IC50 = 4300 nM
   TI
   LI
   LO
   TS
CP0498072
(20S)-4-Methyl-piperazine-1-carboxylic acid 4-ethyl-4-hydroxy-3,13-dioxo-3,4,12,13-tetrahydro-1H-2-oxa-6,12a-diaza-dibenzo[b,h]fluoren-9-yl ester
   Show/Hide
C26H26N4O6
 1
1
IC50 = 4400 nM
   TI
   LI
   LO
   TS
CP0915123
(20RS)-Amino-acetic acid 10-amino-4-ethyl-3,13-dioxo-3,4,12,13-tetrahydro-1H-2-oxa-6,12a-diaza-dibenzo[b,h]fluoren-4-yl ester hydrochloride
   Show/Hide
C22H21ClN4O5
 2
1
IC50 = 5500 nM
   TI
   LI
   LO
   TS
2
IC50 = 6800 nM
   TI
   LI
   LO
   TS
CP0946585
(20RS)-sodium 2-(13-amino-8-hydroxymethyl-9-oxo-9,11-dihydro[1,3]dioxolo[5,4-g]indolizino[1,2-b]quinolin-7-yl)-2-hydroxybutanoate
   Show/Hide
C21H18N3NaO7
 1
1
IC50 = 5500 nM
   TI
   LI
   LO
   TS
CP0510674
(20RS)-4-Hydroxy-4-(2-hydroxy-ethyl)-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione
   Show/Hide
C20H16N2O5
 1
1
IC50 = 9600 nM
   TI
   LI
   LO
   TS
CP0649923
SID50108849
   Show/Hide
C20H17N2NaO5
 1
1
IC50 = 12000 nM
   TI
   LI
   LO
   TS
CP0950236
(20RS)-Sodium salt; 2-(1-amino-8-hydroxymethyl-9-oxo-9,11-dihydro-indolizino[1,2-b]quinolin-7-yl)-2-hydroxy-butyrate
   Show/Hide
C20H18N3NaO5
 1
1
IC50 = 13000 nM
   TI
   LI
   LO
   TS
CP0503346
(20S)-[1,4']Bipiperidinyl-1'-carboxylic acid 4-ethyl-4-hydroxy-3,13-dioxo-3,4,12,13-tetrahydro-1H-2-oxa-6,12a-diaza-dibenzo[b,h]fluoren-9-yl ester
   Show/Hide
C31H34N4O6
 1
1
IC50 = 21000 nM
   TI
   LI
   LO
   TS
CP0405262
(20RS)-10-Amino-7,9-dibromo-4-ethyl-4-hydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione
   Show/Hide
C20H15Br2N3O4
 1
1
IC50 > 30000 nM
   TI
   LI
   LO
   TS
CP0409622
(20RS)-6-Ethyl-6-hydroxy-9,11-dihydro-6H-8-oxa-4,10a-diaza-benzo[b]fluorene-7,10-dione
   Show/Hide
C16H14N2O4
 1
1
IC50 > 30000 nM
   TI
   LI
   LO
   TS
CP0419209
(5R)-16-amino-5-ethyl-5-hydroxy-7,18,20-trioxa-11,24-diazahexacyclo[11.11.0.02,11.04,9.015,23.017,21]tetracosa-1(24),2,4(9),13,15,17(21),22-heptaene-6,10-dione
   Show/Hide
C21H17N3O6
 1
1
IC50 > 30000 nM
   TI
   LI
   LO
   TS
CP0493931
(5R)-5-ethyl-5-hydroxy-7,18,20-trioxa-11,24-diazahexacyclo[11.11.0.02,11.04,9.015,23.017,21]tetracosa-1(13),2,4(9),14,16,21,23-heptaene-6,10-dione
   Show/Hide
C21H16N2O6
 1
1
IC50 > 30000 nM
   TI
   LI
   LO
   TS
CP0503158
sodium;(2R)-2-[14-amino-7-(hydroxymethyl)-8-oxo-16,18-dioxa-2,9-diazapentacyclo[11.7.0.03,11.04,9.015,19]icosa-1(20),2,4,6,11,13,15(19)-heptaen-6-yl]-2-hydroxybutanoate
   Show/Hide
C21H18N3NaO7
 1
1
IC50 > 30000 nM
   TI
   LI
   LO
   TS
CP0516087
(19R)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione
   Show/Hide
C20H16N2O4
 1
1
IC50 > 30000 nM
   TI
   LI
   LO
   TS
Biochemical Assays
Compound ID Compound Name Compound Formula
CP0219181
7-ethyl-7-hydroxy-(7S)-7,8,11,13-tetrahydro-10H-[1,3]dioxolo[4,5-g]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-8,11-dione
   Show/Hide
C21H16N2O6
 3
1 EC50 = 50 nM
2 IC50 = 30 nM
3 IC50 = 78 nM
CP0036977
(S)-4-ethyl-4-hydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]florene-3,13-dione
   Show/Hide
C20H16N2O4
 10
1 EC50 = 350 nM
2 IC50 = 300 nM
3 IC50 = 679 nM
4 IC50 = 700 nM
5 IC50 = 2200 nM
6 IC50 = 2430 nM
7 IC50 = 20000 nM
8 IC50 = 27000 nM
9 IC50 = 62000 nM
10 IC50 = 62900 nM
CP0093295
(S)-10-Dimethylaminomethyl-4-ethyl-4,9-dihydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione; hydrochloride
   Show/Hide
C23H23N3O5
 5
1 IC50 = 50 nM
2 IC50 = 1028 nM
3 IC50 = 1100 nM
4 IC50 = 22880 nM
5 Kd = 26.5 nM
CP0103674
(S)-10-Amino-4-ethyl-4-hydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione
   Show/Hide
C20H17N3O4
 2
1 IC50 = 1800 nM
2 IC50 = 4200 nM
CP0001940
(8S,10S)-10-{[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione
   Show/Hide
C27H29NO11
 1
1 IC50 = 20000 nM
Clinical Information about the Protein
Target 1 ( DNA topoisomerase I (TOP1) )
Target Type Successful Target
Disease 10 Target-related Diseases  10
1 Bacterial infection [ICD-11: 1A00-1C4Z]
2 Colorectal cancer [ICD-11: 2B91.Z]
3 Small-cell lung cancer [ICD-11: 2C25.Y]
4 Solid tumour/cancer [ICD-11: 2A00-2F9Z]
5 Gastric adenocarcinoma [ICD-11: 2B72]
6 Human immunodeficiency virus infection [ICD-11: 1C62]
7 Acquired immune deficiency syndrome [ICD-11: 1C62.3]
8 Breast cancer [ICD-11: 2C60-2C65]
9 Lymphoma [ICD-11: 2A80-2A86]
10 Ovarian cancer [ICD-11: 2C73]
Approved Drug(s) 4 Approved Drugs  4
1 B-Lactams Approved
Bacterial infection
2 Irinotecan Approved
Colorectal cancer
3 Topetecan Approved
Small-cell lung cancer
4 Topotecan Approved
Ovarian cancer
Clinical Trial Drug(s) 13 Clinical Trial Drugs  13
1 Camptothecin Phase 3
Solid tumour/cancer
2 Edotecarin Phase 3
Gastric adenocarcinoma
3 Exatecan Phase 3
Solid tumour/cancer
4 Rubitecan Phase 3
Human immunodeficiency virus infection
5 9-AMINOCAMPTOTHECIN Phase 2
Acquired immune deficiency syndrome
6 Beta-Lapachone Phase 2
Solid tumour/cancer
7 CRLX101 Phase 2
Solid tumour/cancer
8 DIFLOMOTECAN Phase 2
Solid tumour/cancer
9 Gimatecan Phase 2
Breast cancer
10 LE-SN38 Phase 2
Solid tumour/cancer
11 Daniquidone Phase 1
Lymphoma
12 LMP400 Phase 1
Lymphoma
13 LMP744 Phase 1
Solid tumour/cancer
Discontinued Drug(s) 3 Discontinued Drugs  3
1 Lurtotecan Discontinued in Phase 2
Ovarian cancer
2 BE-13793C Terminated
Solid tumour/cancer
3 BN-80245 Terminated
Solid tumour/cancer